Fresenius SE & Co. KGaA
Research Fresenius SE & Co. KGaA (FRE) on Bullrun: market cap EUR 26.52B, P/E 17.0, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFRE
- ExchangeHM
- CountryGermany
- SectorHealthcare
- IndustryMedical Care Facilities
- CurrencyEUR
- Market capEUR 26.52B
- P/E17.0
- Dividend yield2.3%
- Financial periodQ1 2026
- RevenueEUR 5.82B
- Net incomeEUR 435.00M
- Free cash flowEUR 193.00M
- Gross margin26.4%
Valuation Snapshot
latest market cap is EUR 26.52B; P/E is 17.0; dividend yield is 2.3%.
Peer valuation comparison
Latest P/E is 17x versus a Healthcare sector median of 24.46x (30.5% below).
Latest dividend yield is 2.29% versus a Healthcare sector median of 2.11% (8.5% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 26.52B | 17.0 | 2.2% | 1.05 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.05 EUR, yield 2.3%.
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fresenius SE & Co. KGaA's market cap?
Fresenius SE & Co. KGaA's market capitalization is EUR 26.52B.
What is Fresenius SE & Co. KGaA's P/E ratio?
Fresenius SE & Co. KGaA's price-to-earnings (P/E) ratio is 17.0.
Does Fresenius SE & Co. KGaA pay a dividend?
Fresenius SE & Co. KGaA has a dividend yield of 2.3%.
What does Fresenius SE & Co. KGaA do?
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids.